Erythropoietin in cardiovascular diseases: Exploring new avenues

Clinical Science

Volumn 114, Issue 3-4, 2008, Pages 289-291

  Van Der Meer, Peter ^a,b   Van Veldhuisen, Dirk J ^b   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiac ischaemia; Endothelin; Erythropoietin (EPO); Ischaemia reperfusion injury; Natriuretic peptide

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; ERYTHROCYTE; EXERCISE TOLERANCE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; QUALITY OF LIFE; REPERFUSION INJURY; REVASCULARIZATION; ARTICLE; FEMALE; HEART MUSCLE ISCHEMIA; MALE; METABOLISM;

ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

EID: 38949195101     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070392     Document Type: Note

References (16)

1. Yellon, D. M. and Hausenloy, D. J. (2007) Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121-1135
2. Lipsic, E., Schoemaker, R. G., van der Meer, P., Voors, A. A., van Veldhuisen, D. J. and van Gilst, W. H. (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48, 2161-2167
3. Ehrenreich, H., Hasselblatt, M., Dembowski, C. et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495-505
4. Lipsic, E., van der Meer, P., Voors, A. A. et al. (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin α in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. 20, 135-141
5. Piuhola, J., Kerkela, R., Keenan, J. I., Hampton, M. B., Richards, A. M. and Pemberton, C. J. (2008) Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin. Sci. 114, 293-304
6. Kang, D. H., Yoon, K. I. and Han, D. S. (1998) Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol. Dial. Transplant. 13, 2877-2883
7. van der Meer, P., Voors, A. A., Lipsic, E., Smilde, T. D. J., van Gilst, W. H. and van Veldhuisen, D. J. (2004) Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 44, 63-67
8. de Lemos, J. A., Morrow, D. A., Bentley, J. H. et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345, 1014-1021
9. Januzzi, Jr, J. L., Sakhuja, R., O'Donoghue, M. et al. (2006) Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med. 166, 315-320
10. Singh, A. K., Szczech, L., Tang, K. L. et al. (2006) Correction of anemia with epoetin α in chronic kidney disease. N. Engl. J. Med. 355, 2085-98
11. Davis, M. E., Richards, A. M., Nicholls, M. G., Yandle, T. G., Frampton, C. M. and Troughton, R. W. (2006) Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113, 977-985
12. Palazzuoli, A., Silverberg, D., Iovine, F. et al. (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am. Heart J. 152, 1096.e9-1096.e15
13. Lipsic, E., van der Meer, P., Henning, R. H. et al. (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 44, 473-479
14. Kim, Y., Ma, A. G., Kitta, K. et al. (2003) Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 63, 368-377
15. van Veldhuisen, D. J., Dickstein, K., Cohen-Solal, A. et al. (2007) Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 28, 2208-2216
16. van Veldhuisen, D. J. and McMurray, J. J. (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur. J. Heart Failure 29, 110-112